Love Hemp Group PLC - Response to the Latest FSA Novel Foods Update
RNS Number : 9192G
Love Hemp Group PLC
01 April 2022


1 April 2022


Love Hemp Group PLC

("Love Hemp", the "Group", or the "Company")


Love Hemp responds to the latest FSA Novel Foods update

Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), the brand-led consumer goods company focussed on CBD health and wellness solutions, is pleased to announce that it has been included on the latest update from the Food Standard Agency's ("FSA") Public List of CBD products, enabling Love Hemp to progress through to the validation stage in due course.

Love Hemp has worked hard to ensure that our products are of the highest quality standards and meet all requirements as stipulated by any regulatory body. The FSA's latest Public List endorses all of our submitted products and enables Love Hemp to continue to trade legally. Importantly, the FSA's decision also provides clarity for consumers.

Love Hemp had submitted multiple individual products at the beginning of this process, two years ago, and has invested initially over £300,000 to ensure it received the best legal and scientific advice for a successful application. As part of the manufacturing and production process, Love Hemp is one of the few brands with an in-house Quality Assurance team which gathers and catalogues invaluable product and study data to ensure quality control.

Yesterday's announcement from the FSA confirms that Love Hemp is well positioned to accelerate its growth plans with existing and prospective sales channels, high street retailers, business to business, alongside our own e-commerce platforms, direct to consumer.

We are happy to provide any further detail that may be requested by the FSA and look forward to the next stages of this process. We also echo our congratulations to the other CBD brands that have been included on the FSA's Public List.

Adam Pritchard, Chief Commercial Officer of Love Hemp, said: "We note today's update from the FSA and are delighted with the results. As an award-winning and trusted CBD brand we have always been committed to creating the highest quality, 100% natural, products. The CBD industry in the UK has been largely unregulated, resulting in a lack of clarity for our consumers and we welcome progress made to date by the FSA. We continue to work closely with the FSA and look forward to the next stage of the process, proceeding to validation followed by full approvals."



For further information please visit: or contact: 


Love Hemp Group

Andrew Male
Chairman & Director


+44 (0) 7926 397 675


Financial PR

Tim Blythe/Madeleine Gordon-Foxwell



+44 (0) 207 138 3204



About Love Hemp Group

Love Hemp Group is a brand-led consumer goods company focussed on health and wellness solutions for consumer use cases including sleep, pain, anxiety, stress and recovery. The Company is a pioneer in the UK-based premium high-quality CBD market, with over 40 products including oils, edibles, sprays, cosmetics and topicals. The Company's range of products are sold online across 70 websites and in over 2,000 stores including some of the biggest retailers in the UK, such as Holland & Barrett, Boots and Ocado. Listed on the Aquis Stock Exchange (AQSE: LIFE) the Company recently changed its name to Love Hemp Group plc, from World High Life, to better reflect its focus on supporting the "best in class" CBD brand as it embarks on a wider expansion of its core business and offering.


This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.